It looks like it's all downhill from here. SNSS has eliminated every key member on its research team and is now focusing on one drug candidate that has no hope and will most likely fail somewhere in clinical trials (SNS-595). With only about 30 million left in assets, this company will only survive for one more year at the most. I just sold all my shares today before this thing hits rock bottom. Good luck.